Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label study of E7090 in unresectable or metastatic FGFR2 fusion-positive cholangiocarcinoma
CTR20200337Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tasurgratinib in cholangiocarcinoma (CCA), sponsored by Eisai Co., Ltd.. Started Dec 2020; status: completed.
02
Drugs
tasurgratinib
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on CTR20200337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200337.